{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:27:53Z","timestamp":1791379673876,"version":"4.3.3"},"reference-count":124,"publisher":"Korean Society for the Study of Obesity","issue":"2","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["www.jomes.org"],"crossmark-restriction":true},"short-container-title":["Journal of Obesity & Metabolic Syndrome"],"published-print":{"date-parts":[[2026,4,30]]},"DOI":"10.7570\/jomes25083","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:58:03Z","timestamp":1772499483000},"page":"130-149","update-policy":"https:\/\/doi.org\/10.7570\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Current Trends and Perspectives on Obesity and Metabolic Dysfunction-Associated Steatohepatitis in East Asia"],"prefix":"10.7570","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4137-1671","authenticated-orcid":false,"given":"Soo","family":"Lim","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3230-2917","authenticated-orcid":false,"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0432-4366","authenticated-orcid":false,"given":"Wataru","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Division of Translational Science, Section of Metabolic Diseases, Kobe University Graduate School of Medicine, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4370","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"ref1","unstructured":"World Health Organization. Obesity and overweight [Internet]. WHO; 2025 [cited 2026 Mar 2]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesityand-overweight"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70161"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2025.102584"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29466"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0431"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.03.040"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000004"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2021.04.008"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.5370"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2022.155217"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30039-1"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31150"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-40116-9_8"},{"key":"ref14","unstructured":"World Health Organization, Regional Office for the Western Pacific. The Asia-Pacific perspective: redefining obesity and its treatment. Health Communications Australia; 2000."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.puhe.2024.09.021"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15014"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.05.036"},{"key":"ref18","unstructured":"Global Obesity Observatory. Japan trends over time [Internet]. World Obesity Federation; 2026 [cited 2026 Mar 2]. Available from: https:\/\/data.worldobesity.org\/country\/japan-105\/#data_trends"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.155789"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2020.06.022"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12247634"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.7570\/jomes22024"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18451"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00318-8"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2147\/PGPM.S463608"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-024-01106-8"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58091271"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-024-10774-3"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/86.2.353"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.112.035758"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2015.07.024"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15046"},{"key":"ref33","unstructured":"Sato-Espinoza K, Chotiprasidhi P, Huaman MR, D\u00edaz-Ferrer J. Update in lean metabolic dysfunction-associated steatotic liver disease. World J Hepatol 2024;16:452-64."},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.06.003"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(20)30077-7"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2025.101780"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/ng.257"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2012.65"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbae389"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.575049"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.39030"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.35772\/ghm.2023.01121"},{"key":"ref43","unstructured":"Kang M, Choi YJ, Kim Y, You S, Kim Y, Fried C. Sustainability and resilience in the Republic of Korea health system [Internet]. Center for Asia-Pacific Resilience and Innovation (CAPRI); 2024 [cited 2026 Mar 2]. Available from: https:\/\/www3.weforum.org\/docs\/WEF_PHSSR_CAPRI_Korea_2024.pdf"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf130"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.50240"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.594150"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-024-00937-w"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.08.019"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0358"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.afos.2025.05.001"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0310646"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.14387"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.15420\/japsc.2023.68"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.327"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28697"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2015.09.007"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-014-0973-8"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00047-4"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2024.00311"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2025.0045"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2024.0541"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-021-01796-x"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06196-3"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.03.005"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-025-02224-0"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-024-02096-w"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.11.048"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.03.006"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2024.10.008"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ23-0593"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.7570\/jomes23016"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.3390\/nu16172877"},{"key":"ref73","unstructured":"Health Insurance Bureau of the Ministry of Health, Labour and Welfare. Important points to note regarding the partial revision of the medical fee calculation method [Internet]. MHLW; 2025 [cited 2026 Mar 2]. Available from: https:\/\/www.mhlw.go.jp\/content\/10800000\/001564622.pdf"},{"key":"ref74","unstructured":"Madrigal Pharma. REZDIFFRA (resmetirom) prescribing information [Internet]. Madrigal Pharma; 2024 [cited 2026 Mar 2]. Available from: https:\/\/www.madrigalpharma.com\/wp-content\/uploads\/2024\/03\/Prescribing-Information.pdf"},{"key":"ref75","unstructured":"Madrigal Pharma. Madrigal receives European commission approval for RezdiffraTM (resmetirom) for the treatment of MASH with moderate to advanced liver fibrosis [Internet]. Madrigal Pharma; 2025 [cited 2026 Mar 2]. Available from: https:\/\/ir.madrigalpharma.com\/node\/16716\/pdf"},{"key":"ref76","unstructured":"Novo Nordisk. Novo Nordisk A\/S: Wegovy\u00ae approved in the US for the treatment of MASH [Internet]. Novo Nordisk; 2025 [cited 2026 Mar 2]. Available from: https:\/\/www.novonordisk.com\/content\/nncorp\/global\/en\/news-andmedia\/news-and-ir-materials\/news-details.html?id=916416"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309000"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2025.2473062"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2022.03.005"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401755"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00356-X"},{"key":"ref83","unstructured":"ClinicalTrials.gov. A study comparing IBI362 vs Semaglutide in chinese overweight or obese adults with metabolic dysfunction-associated fatty liver disease (MAFLD) [Internet]. National Library of Medicine; 2025 [cited 2026 Mar 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06884293"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411528"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00272-8"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304286"},{"key":"ref87","unstructured":"Akero Therapeutics. Akero therapeutics announces initiation of phase 3 SYNCHRONY outcomes trial of efruxifermin in patients with compensated cirrhosis (F4) due to MASH [Internet]. Akero Therapeutics; 2024 [cited 2026 Mar 2]. Available from: https:\/\/www.biospace.com\/akero-therapeuticsannounces-initiation-of-phase-3-synchrony-outcomes-trial-ofefruxifermin-in-patients-with-compensated-cirrhosis-f4-dueto-mash"},{"key":"ref88","unstructured":"89bio Inc. 89bio initiates phase 3 ENLIGHTEN-cirrhosis trial of pegozafermin in metabolic dysfunction-associated steatohepatitis (MASH) patients with compensated cirrhosis [Internet]. 89bio; 2024 [cited 2026 Mar 2]. Available from: https:\/\/ir.89bio.com\/news-releases\/news-release-details\/89bio-initiates-phase-3-enlighten-cirrhosis-trial-pegozafermin\/"},{"key":"ref89","unstructured":"ClinicalTrials.gov. LIVERAGETM - Cirrhosis: a study to test whether survodutide helps people with a liver disease called NASH\/MASH who have cirrhosis [Internet]. National Library of Medicine; 2026 [cited 2026 Mar 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06632457"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1195146"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2008.09.003"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70029"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.123.001045"},{"key":"ref94","unstructured":"Chen M. Obesity injection treatment receives regulatory approval [Internet]. China Daily; 2023 [cited 2026 Mar 2]. Available from: https:\/\/www.chinadaily.com.cn\/a\/202307\/05\/WS64a55749a310bf8a75d6d6c4.html"},{"key":"ref95","unstructured":"Silver A. Novo Nordisk's Wegovy weight-loss drug approved in China [Internet]. Reuters; 2024 [cited 2026 Mar 2]. Available from: https:\/\/www.reuters.com\/business\/healthcarepharmaceuticals\/novo-nordisk-says-semaglutide-approvedlong-term-weight-management-china-2024-06-25\/"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15360"},{"key":"ref97","unstructured":"Silver A. Eli Lilly's weight loss drug tirzepatide gets approval in China [Internet]. Reuters; 2024 [cited 2026 Mar 2]. Available from: https:\/\/www.reuters.com\/business\/healthcarepharmaceuticals\/eli-lillys-weight-loss-drug-tirzepatide-getsapproval-china-2024-07-19\/"},{"key":"ref98","unstructured":"PR Newswire. Innovent announces mazdutide, first dual GCG\/GLP-1 receptor agonist, received approval from China's NMPA for chronic weight management [Internet]. PR Newswire; 2025 [cited 2026 Mar 2]. Available from: https:\/\/www.prnewswire.com\/news-releases\/innovent-announcesmazdutide-first-dual-gcgglp-1-receptor-agonist-receivedapproval-from-chinas-nmpa-for-chronic-weight-management-302493152.html"},{"key":"ref99","unstructured":"Choi M. Obesity drug Wegovy launched in Korea at 370,000 won [Internet]. Business Korea; 2024 [cited 2026 Mar 2]. Available from: https:\/\/www.businesskorea.co.kr\/news\/articleView.html?idxno=227001"},{"key":"ref100","unstructured":"Lee H. Lilly's diabetes drug Mounjaro receives expanded approval for weight management in Korea [Internet]. Korea Biomedical Review; 2024 [cited 2026 Mar 2]. Available from: https:\/\/www.koreabiomed.com\/news\/articleView.html?idxno=24730"},{"key":"ref101","unstructured":"Mitsubishi Tanabe Pharma. \"Zepbound\u00ae\", a long-acting GIP\/GLP-1 receptor agonist, approved for the chronic disease of \"obesity disease\" with multiple factors [Internet]. Mitsubishi Tanabe Pharma; 2024 [cited 2026 Mar 2]. Available from: https:\/\/www.mt-pharma.co.jp\/e\/news\/assets\/pdf\/e_MTPC241227.pdf"},{"key":"ref102","unstructured":"Pharmaceuticals and Medical Devices Agency. List of Approved Drugs April 2004 to December 2024 [Internet]. PMDA; 2025 [cited 2026 Mar 2]. Available from: https:\/\/www.pmda.go.jp\/files\/000274881.pdf"},{"key":"ref103","unstructured":"The Japan Times. Japan's first over-the-counter anti-obesity drug to hit stores in April [Internet]. The Japan Times; 2024 [cited 2026 Mar 2]. Available from: https:\/\/www.japantimes.co.jp\/news\/2024\/03\/05\/japan\/science-health\/anti-obesitydrug\/"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02941-7"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2024.101741"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.3390\/life14091073"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-017-0596-2"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15837"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1177\/20552076231182789"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2009.05914.x"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2009.06026.x"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-018-5389-5"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12196216"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1111\/apt.70020"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100142"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2022.12.005"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00118-2"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-023-16855-6"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.36469\/jheor.2024.123991"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ23-0416"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.70000"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-022-00370-2"},{"key":"ref123","unstructured":"Health and Global Policy Institute. Policy Recommendations. Obesity control promotion project 2023 \"The next steps for engaging and cooperating with patients, citizens, and communities for implements of obesity control measurements\" (April 8, 2024) [Internet]. HGPI; 2024 [cited 2026 Mar 2]. Available from: https:\/\/hgpi.org\/en\/research\/ncd-ob-20240304.html"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1016\/j.glohj.2022.07.007"}],"container-title":["Journal of Obesity & Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pdf.medrang.co.kr\/KSSO2\/2026\/035\/jomes-35-2-130.pdf","content-type":"unspecified","content-version":"tdm","intended-application":"text-mining"},{"URL":"https:\/\/pdf.medrang.co.kr\/KSSO2\/2026\/035\/jomes-35-2-130.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T01:35:42Z","timestamp":1778463342000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jomes.org\/journal\/view.html?doi=10.7570\/jomes25083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":124,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4,30]]}},"alternative-id":["10.7570\/jomes25083"],"URL":"https:\/\/doi.org\/10.7570\/jomes25083","relation":{},"ISSN":["2508-6235","2508-7576"],"issn-type":[{"value":"2508-6235","type":"print"},{"value":"2508-7576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"http:\/\/www.jomes.org\/journal\/view.html?doi=10.7570\/jomes25083","URL":"http:\/\/www.jomes.org\/journal\/view.html?doi=10.7570\/jomes25083","name":"the_journal","label":"J Obes Metab Syndr","group":{"name":"multiple_resolution","label":"Full text available at:"}},{"value":"2025-09-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-03","order":3,"name":"published","label":"Online First","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-30","order":4,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}},{"value":"\u00a9 2026 The Korean Society for the Study of Obesity","name":"copyright","label":"Copyright","group":{"name":"Copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.","name":"license","label":"License","explanation":{"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},"group":{"name":"Copyright_and_licensing","label":"Copyright and Licensing"}}]}}